The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Skin Toxicity Evaluation Protocol With Panitumumab (STEPP), a Phase II, Open-Label, Randomized Trial Evaluating the Impact of a Pre-Emptive Skin Treatment Regimen on Skin Toxicities and Quality of Life in Patients With Metastatic Colorectal Cancer
Abstract
Purpose: Panitumumab, a fully human monoclonal antibody targeting the epidermal growth factor receptor (EGFR), is approved in the United States and Europe for the treatment of refractory metastatic colorectal cancer (mCRC). Skin toxicities are the most common adverse events with EGFR inhibitors. This is the first study designed to examine differences between pre-emptive and reactive skin treatment for specific skin toxicities in patients with mCRC for any EGFR inhibitor. Patients and Methods: Patients receiving panitumumab-containing therapy were randomly assigned 1:1 to pre-emptive or reactive treatment (after skin toxicity developed). Pre-emptive treatment included use of skin moisturizers, sunscreen, topical steroid, and doxycycline. The primary end point of the study was the incidence of protocol-specified ≥ grade 2 skin toxicities during the 6-week skin treatment period. Quality of life (QOL) was assessed with the Dermatology Life Quality Index (DLQI). Results: Of 95 enrolled patients, 48 received pre-emptive treatment, and 47 received reactive treatment. The incidence of protocol-specified ≥ grade 2 skin toxicities during the 6-week skin treatment period was 29% and 62% for the pre-emptive and reactive groups, respectively. Mean DLQI score change from baseline to week 3 was 1.3 points and 4.2 points in the pre-emptive and reactive groups, respectively. Conclusion: The pre-emptive skin treatment regimen was well tolerated. The incidence of specific ≥ grade 2 skin toxicities during the 6-week skin treatment period was reduced by more than 50% in the pre-emptive group compared with the reactive group. Patients in the pre-emptive group reported less QOL impairment than patients in the reactive group.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use
FINLAY, A. Y., & KHAN, G. K. (1994) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.1994.tb01167.x · Cited by 5,586
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
ERBB receptors and cancer: the complexity of targeted inhibitors
Hynes, N. E., & Lane, H. A. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1609 · Cited by 3,313
Epidermal growth factor-related peptides and their receptors in human malignancies
Salomon, D. S., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,690
Van Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1620 · Cited by 1,979
Cetuximab for the Treatment of Colorectal Cancer
Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071834 · Cited by 1,904
Cetuximab in the treatment of colorectal cancer.
Goldberg, R. M., Venook, A. P., & Schilsky, R. L. (2004) · PubMed · Cited by 1,518
Hecht, J. R., Mitchell, E., Chidiac, T., Scroggin, C., Hagenstad, C., Spigel, D., Marshall, J., Cohn, A., McCollum, D., Stella, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8135 · Cited by 850
Self-citationMechanisms of cutaneous toxicities to EGFR inhibitors
Lacouture, M. E. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1970 · Cited by 789
Self-citationTetracyclines: Nonantibiotic properties and their clinical implications
Sapadin, A. N., & Fleischmajer, R. (2006) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2005.10.004 · Cited by 768
Cutaneous Adverse Effects With HER1/EGFR-Targeted Agents: Is There a Silver Lining?
Peréz-Soler, R., & Saltz, L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.6916 · Cited by 486
Busam, K. J., Capodieci, P., Motzer, R., Kiehn, T., Phelan, D., & Halpern, A. C. (2001) · British Journal of Dermatology · doi:10.1046/j.1365-2133.2001.04226.x · Cited by 419
Wacker, B., Nagrani, T., Weinberg, J., Witt, K., Clark, G., & Cagnoni, P. J. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2610 · Cited by 384
Scope, A., Agero, A. L. C., Dusza, S. W., Myskowski, P. L., Lieb, J. A., Saltz, L., Kemeny, N. E., & Halpern, A. C. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.6987 · Cited by 278
The clinical benefit of moisturizers
Lodén, M. (2005) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2005.01326.x · Cited by 255
Jatoi, I., Chen, B. E., Anderson, W. F., & Rosenberg, P. S. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2106 · Cited by 211
Boone, S. L., Rademaker, A., Liu, D., Pfeiffer, C., Mauro, D. J., & Lacouture, M. E. (2007) · Oncology · doi:10.1159/000112795 · Cited by 190
Self-citationRowinsky, E. K. (2004) · Annual Review of Medicine · doi:10.1146/annurev.med.55.091902.104433 · Cited by 178
Eilers, R. E., Gandhi, M., Patel, J. D., Mulcahy, M. F., Agulnik, M., Hensing, T., & Lacouture, M. E. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp439 · Cited by 167
Self-citationSegaert, S., Tabernero, J. M., Chosidow, O., Dirschka, T., Elsner, J., Mancini, L. L., Maughan, T., Morère, J., Santoro, A., Sobrero, A. F., et al. (2005) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/j.1610-0387.2005.05058.x · Cited by 130
Wagner, L. I., & Lacouture, M. E. (2007) · PubMed · Cited by 118
Self-citationChallenges in the Use of Epidermal Growth Factor Receptor Inhibitors in Colorectal Cancer
Cutsem, E. V. (2006) · The Oncologist · doi:10.1634/theoncologist.11-9-1010 · Cited by 56
Photosensitive rash due to the epidermal growth factor receptor inhibitor erlotinib
Luu, M., Lai, S. E., Patel, J. D., et al. (2007) · Photodermatology Photoimmunology & Photomedicine · doi:10.1111/j.1600-0781.2007.00273.x · Cited by 53
Jost, M., Gasparro, F. P., Rodeck, U., & Jensen, P. J. (2001) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2001.01356.x · Cited by 36
Cutsem, E. V. (2007) · Clinical Colorectal Cancer · doi:10.3816/ccc.2007.s.004 · Cited by 13
Cited by
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112302 · Cited by 2,156
Douillard, J.-Y., Siena, S., Cassidy, J., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4860 · Cited by 1,809
Schmoll, H. J., Van Cutsem, E., Stein, A., Valentini, V., Glimelius, B., Haustermans, K., Nordlinger, B., van de Velde, C. J., Balmana, J., Regula, J., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds236 · Cited by 1,510
Lacouture, M. E., Anadkat, M. J., Bensadoun, R.-J., Bryce, J., Chan, A., Epstein, J. B., Eaby-Sandy, B., Murphy, B. A., & MASCC Skin Toxicity Study Group (2011) · Supportive Care in Cancer · doi:10.1007/s00520-011-1197-6 · Cited by 444
Self-citationSotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C
Fakih, M. G., Salvatore, L., Esaki, T., Modest, D. P., Lopez-Bravo, D. P., Taieb, J., Karamouzis, M. V., Ruiz-Garcia, E., Kim, T.-W., Kuboki, Y., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2308795 · Cited by 398
Metadata
- Authors
- Lacouture, M. E., Mitchell, E. P., Piperdi, B., Pillai, M. V., Shearer, H., Iannotti, N., Xu, F., & Yassine, M.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-03-10
- Volume
- 28
- Issue
- 8
- Pages
- 1351-1357
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2160344439
- Cited by
- 478
- References
- 26
- FWCI
- 48.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.